Study of Arrhythmia and ECG Abnormalities in Patients With COVID-19
Overview
- Phase
- N/A
- Intervention
- ECG data analysis
- Conditions
- Arrhythmia
- Sponsor
- University Hospital, Bordeaux
- Enrollment
- 196
- Locations
- 1
- Primary Endpoint
- Proportion of ECGs abnormalities in patients SARS-CoV-2 infection
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
Cardiac involvement has been described in Severe Acute Respiratory Syndrome - Coronavirus-2 (SARS-CoV-2) infection. Although there are no approved drugs to prevent or treat SARS-CoV-2 infection at present time, several medications used have the potential to increase QT interval and eventually provoke torsades de pointe. The investigators therefore create a study that include all patients with SARS-CoV-2 infection having an electrocardiogram (ECG). The investigators evaluate the percentage of patients with ECG abnormalities, describe the abnormalities and evaluate the occurrence of syncope, ventricular arrhythmia and corrected QT (cQT) interval modification in patients receiving treatment.
Detailed Description
In patients with SARS-CoV-2 infection, the investigators analyze baseline ECG as well as follow-up ECG. Patients followed by Bordeaux University Hospital for COVID-19 can be included. ECG are digitized in the computerized patient file (DxCARE) for further analysis.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients over 18 years of both gender,
- •Followed by Bordeaux University Hospital for SARS-CoV-2 infection with a cardiac monitoring or ECG realized.
- •Non opposition expressed.
Exclusion Criteria
- •Inability to understand the study
Arms & Interventions
SARS-CoV-2 infection
This group includes patients prospectively included during their follow-up at the Bordeaux University Hospital for COVID-19, as well as retrospectively included patients whose follow-up for COVID-19 has been completed.
Intervention: ECG data analysis
SARS-CoV-2 infection
This group includes patients prospectively included during their follow-up at the Bordeaux University Hospital for COVID-19, as well as retrospectively included patients whose follow-up for COVID-19 has been completed.
Intervention: Treatment data collect
SARS-CoV-2 infection
This group includes patients prospectively included during their follow-up at the Bordeaux University Hospital for COVID-19, as well as retrospectively included patients whose follow-up for COVID-19 has been completed.
Intervention: Biological check-up data collect
SARS-CoV-2 infection
This group includes patients prospectively included during their follow-up at the Bordeaux University Hospital for COVID-19, as well as retrospectively included patients whose follow-up for COVID-19 has been completed.
Intervention: Collection of clinical events of interest
Outcomes
Primary Outcomes
Proportion of ECGs abnormalities in patients SARS-CoV-2 infection
Time Frame: Day 0
Percentage of ECGs with abnormalities
Secondary Outcomes
- Rate of cardiac death during treatment(Baseline and 1 month)
- Evolution of PR, QRS and cQT interval(Baseline and 1 month)
- Rate of syncope during treatment(Baseline and 1 month)
- Rate of arrhythmia during treatment(Baseline and 1 month)